Daniele Urso, MD, Kings College London, London, UK, describes a recent review article exploring some of the key challenges associated with the administration of levodopa for the treatment of Parkinson’s disease (PD), including limitations on tablet capsule size via oral administration, poor absorption in the gut, enzymatic instability and difficulties entering the brain. Novel approaches and technologies aiming to improve levodopa delivery are currently under investigation, including non-oral therapies administered via the intranasal route, devices for subcutaneous administration and novel sustained and controlled release formulations. This interview took place during the AD/PD™ 2021 conference.